Acarix AB (ACARIX) Fair Value & Analysis
Healthcare · SE · Market cap 298M SEK
Fair value as of: Jul 15, 2026
From 1 valuation models · updated 26 days ago
Share price −0.6% over the past month.
Below-average quality, and screening another 90% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (kr 0.0255). The favourable scenario is already priced in.
- Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.
How to read this chart
60‑month range kr 0.1776 – kr 1.37 · fair‑value band kr 0.0170 – kr 0.0255 · the kr 0.2525 price screens above the kr 0.0255 fair value. Dashed = 300-day average. As of Jul 15, 2026.
Analysis
Acarix AB (ACARIX) currently trades at kr 0.2525, while our model-based Fair Value estimate is kr 0.0255, implying the stock looks roughly 89.9% overvalued today. The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 8.1M SEK. Revenue grew 40.2% year over year. It earns a return on equity of -88.3%. The balance sheet holds a net cash position of 18.3M SEK. Fundamentals as of Jul 15, 2026
Our scenario range runs from kr 0.0170 (bear case) to kr 0.0255 (bull case); at kr 0.2525, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 46% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -90%, ACARIX screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when ACARIX reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 35 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care.
Full company description
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Acarix AB reported revenue of kr 7.4M in FY2025 versus kr 3.8M in FY2021, a compound +18.3%/yr. Reported net income was −kr 48.1M in FY2025.
ACARIX screens 90% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Acarix AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Acarix AB (ACARIX) overvalued or undervalued?
What is the fair value of ACARIX?
What is the quality score of ACARIX?
What is the revenue of Acarix AB (ACARIX)?
What is the net profit margin of ACARIX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Acarix AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.